For example, LCK activity could improve T-cell responses in cancer immunotherapy (57), and STAT1 expression was demonstrated as a potential biomarker for anti-PD-1/anti-PD-L1 for cancer patients (58, 59). This evidence concerns the gene PDCD1 and cancer.